Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Mar;15(3):213-5.
doi: 10.1038/ni.2826.

A new RIDDle in DC-mediated cross-presentation

Affiliations
Comment

A new RIDDle in DC-mediated cross-presentation

Manikandan Subramanian et al. Nat Immunol. 2014 Mar.

Abstract

Hyperactivity of a branch of the unfolded protein response in CD8α+ dendritic cells degrades endoplasmic reticulum–associated mRNAs, which leads to a defect in the cross-presentation of dead cell–derived antigens.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Possible mechanisms by which RIDD compromises the cross-presentation of dead cell–derived antigens in CD8α+ DCs. Deletion of XBP-1 (XBP-1Δ) in CD8α+ DCs leads to hyperactivation of IRE-1α, which leads to the cleavage of multiple mRNAs by endonucleases (RIDD). The main consequence observed by Osorio et al. is defective cross-presentation of dead cell–derived antigens. In theory, one or more mRNAs encoding proteins involved in the various stages of antigen cross-presentation (bold purple font) could be relevant targets of RIDD. Osorio et al. have identified several mRNA substrates of RIDD that could be involved, such as Lamp1, Tapbp and Ergic3, but the roles of their products remain to be demonstrated. Moreover, the specificity for dead cell–derived antigens rather than soluble or endogenous antigens raises the possibility that one or more molecules involved in the uptake and/or processing of dead cells may be the relevant targets of RIDD. TCR, T cell antigen receptor; MHCI, MHC class I.

Comment on

Similar articles

Cited by

References

    1. Joffre OP, Segura E, Savina A, Amigorena S. Nat. Rev. Immunol. 2012;12:557–569. - PubMed
    1. Osorio F, et al. Nat. Immunol. 2014;15:248–257. - PubMed
    1. Hollien J, Weissman JS. Science. 2006;313:104–107. - PubMed
    1. Ron D, Hubbard SR. Cell. 2008;132:24–26. - PubMed
    1. So JS, et al. Cell Metab. 2012;16:487–499. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources